## Anat Loewenstein

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6083303/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). British Journal of Ophthalmology, 2014, 98, 1144-1167.	3.9	463
2	Early and Long-Term Responses to Anti–Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data. American Journal of Ophthalmology, 2016, 172, 72-79.	3.3	259
3	2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations. Ophthalmologica, 2018, 239, 181-193.	1.9	195
4	OCT Biomarkers as Functional Outcome Predictors in Diabetic Macular Edema Treated with Dexamethasone Implant. Ophthalmology, 2018, 125, 267-275.	5.2	188
5	Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet, The, 2022, 399, 741-755.	13.7	166
6	Guidelines for the Management of Retinal Vein Occlusion by the European Society of Retina Specialists (EURETINA). Ophthalmologica, 2019, 242, 123-162.	1.9	153
7	DEXAMETHASONE IMPLANT FOR DIABETIC MACULAR EDEMA IN NAIVE COMPARED WITH REFRACTORY EYES. Retina, 2019, 39, 44-51.	1.7	130
8	Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti–vascular endothelial growth factor therapy of macular diseases. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 1259-1273.	1.9	113
9	Replacing the Amsler grid. Ophthalmology, 2003, 110, 966-970.	5.2	108
10	Dexamethasone intravitreal implant in the treatment of diabetic macular edema. Clinical Ophthalmology, 2015, 9, 1321.	1.8	101
11	Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic. Graefe's Archive for Clinical and Experimental Ophthalmology, 2020, 258, 1149-1156.	1.9	97
12	Nonadherence or Nonpersistence to Intravitreal Injection Therapy for Neovascular Age-Related Macular Degeneration. Ophthalmology, 2021, 128, 234-247.	5.2	95
13	Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema. Acta Diabetologica, 2018, 55, 789-796.	2.5	91
14	The Role of Steroids in the Management of Diabetic Macular Edema. Ophthalmic Research, 2019, 62, 231-236.	1.9	86
15	Eplerenone for chronic central serous chorioretinopathy–a randomized controlled prospective study. Acta Ophthalmologica, 2017, 95, e610-e618.	1.1	85
16	Automated Identification of Lesion Activity in Neovascular Age-Related Macular Degeneration. Ophthalmology, 2016, 123, 1731-1736.	5.2	83
17	A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 463-473.	1.9	83
18	Cost-effectiveness of diabetic retinopathy screening programs using telemedicine: a systematic review. Cost Effectiveness and Resource Allocation, 2020, 18, 16.	1.5	77

#	Article	IF	CITATIONS
19	Disorganization of retinal inner layers as a biomarker in patients with diabetic macular oedema treated with dexamethasone implant. Acta Ophthalmologica, 2020, 98, e217-e223.	1.1	75
20	Progression of diabetic retinopathy severity after treatment with dexamethasone implant: a 24-month cohort study the †DR-Pro-DEX Study'. Acta Diabetologica, 2018, 55, 541-547.	2.5	74
21	Transforming ophthalmic education into virtual learning during COVID-19 pandemic: a global perspective. Eye, 2021, 35, 1459-1466.	2.1	69
22	Optic disc pit maculopathy: when and how to treat? A review of the pathogenesis and treatment options. International Journal of Retina and Vitreous, 2015, 1, 13.	1.9	68
23	Disorganization of Retinal Inner Layers as a Biomarker for Idiopathic Epiretinal Membrane After Macular Surgery—The DREAM Study. American Journal of Ophthalmology, 2018, 196, 129-135.	3.3	66
24	Retinal Pathology Occurring after Excimer Laser Surgery or Phakic Intraocular Lens Implantation. Survey of Ophthalmology, 2002, 47, 125-135.	4.0	58
25	The suprachoroidal space: from potential space to a space with potential. Clinical Ophthalmology, 2016, 10, 173.	1.8	58
26	First-line treatment algorithm and guidelines in center-involving diabetic macular edema. European Journal of Ophthalmology, 2019, 29, 573-584.	1.3	58
27	Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmology, 2015, 15, 150.	1.4	57
28	A Review of Innovations in Rhegmatogenous Retinal Detachment Surgical Techniques. Journal of Ophthalmology, 2017, 2017, 1-5.	1.3	55
29	ASSOCIATION BETWEEN EARLY ANATOMIC RESPONSE TO ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY AND LONG-TERM OUTCOME IN DIABETIC MACULAR EDEMA. Retina, 2019, 39, 88-97.	1.7	55
30	Faricimab: expanding horizon beyond VEGF. Eye, 2020, 34, 802-804.	2.1	54
31	Non-neovascular age-related macular degeneration with subretinal fluid. British Journal of Ophthalmology, 2021, 105, 1415-1420.	3.9	51
32	Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results. Acta Diabetologica, 2019, 56, 1341-1350.	2.5	49
33	THE SIGNIFICANCE OF EARLY DETECTION OF AGE-RELATED MACULAR DEGENERATION. Retina, 2007, 27, 873-878.	1.7	47
34	Biomarkers and predictors for functional and anatomic outcomes for small gauge pars plana vitrectomy and peeling of the internal limiting membrane in naÃ⁻ve diabetic macular edema: The VITAL Study. PLoS ONE, 2018, 13, e0200365.	2.5	45
35	Early detection of age related macular degeneration: current status. International Journal of Retina and Vitreous, 2015, 1, 20.	1.9	44
36	THE ANGIOPOIETIN/TIE PATHWAY IN RETINAL VASCULAR DISEASES. Retina, 2021, 41, 1-19.	1.7	44

#	Article	IF	CITATIONS
37	TRActional Dlabetic reTInal detachment surgery with co-adjuvant intravitreal dexamethasONe implant: the TRADITION STUDY. Acta Diabetologica, 2019, 56, 1141-1147.	2.5	42
38	A Collaborative Retrospective Study on the Efficacy and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema. Ophthalmology, 2020, 127, 377-393.	5.2	40
39	Cavernous haemangioma of the orbit: Treatment by transconjunctival cryoextraction. Eye, 1993, 7, 597-598.	2.1	39
40	Topical dexamethasone–cyclodextrin nanoparticle eye drops for nonâ€infectious Uveitic macular oedema and vitritis – a pilot study. Acta Ophthalmologica, 2015, 93, 411-415.	1.1	38
41	Choroidal Anatomic Alterations After Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: A Multicenter Study. American Journal of Ophthalmology, 2020, 217, 104-113.	3.3	36
42	Detection of Diabetic Retinopathy from Ultra-Widefield Scanning Laser Ophthalmoscope Images: A Multicenter Deep Learning Analysis. Ophthalmology Retina, 2021, 5, 1097-1106.	2.4	36
43	Brolucizumab and immunogenicity. Eye, 2020, 34, 1726-1728.	2.1	34
44	Oral Rifampin treatment for longstanding chronic central serous chorioretinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254, 15-22.	1.9	33
45	Biosimilars for Retinal Diseases: An Update. American Journal of Ophthalmology, 2021, 224, 36-42.	3.3	33
46	Automated Quantitative Assessment of Retinal Fluid Volumes as Important Biomarkers in Neovascular Age-Related Macular Degeneration. American Journal of Ophthalmology, 2021, 224, 267-281.	3.3	33
47	Fundamental principles of an effective diabetic retinopathy screening program. Acta Diabetologica, 2020, 57, 785-798.	2.5	32
48	Next-generation anti-VEGF agents for diabetic macular oedema. Eye, 2022, 36, 273-277.	2.1	30
49	Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspective. British Journal of Ophthalmology, 2020, 104, 2-7.	3.9	29
50	Abicipar pegol—a novel anti-VEGF therapy with a long duration of action. Eye, 2020, 34, 605-606.	2.1	28
51	Real-world outcomes of observation and treatment in diabetic macular edema with very good visual acuity: the OBTAIN study. Acta Diabetologica, 2019, 56, 777-784.	2.5	27
52	Outer retinal hyperreflective deposits (ORYD): a new OCT feature in naÃ⁻ve diabetic macular oedema after PPV with ILM peeling. British Journal of Ophthalmology, 2020, 104, 666-671.	3.9	27
53	Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data. Eye, 2020, 34, 480-490.	2.1	27
54	Adipose-Derived Mesenchymal Stem Cells Migrate and Rescue RPE in the Setting of Oxidative Stress. Stem Cells International, 2018, 2018, 1-11.	2.5	24

#	Article	IF	CITATIONS
55	Effect of Baseline Subretinal Fluid on Treatment Outcomes in VIVID-DME and VISTA-DME Studies. Ophthalmology Retina, 2019, 3, 663-669.	2.4	24
56	Bevacizumab treatment of macular edema in CRVO and BRVO: long-term follow-up. (BERVOLT study:) Tj ETQqO Ophthalmology, 2016, 254, 835-844.	0 0 rgBT // 1.9	Overlock 10 T 23
57	Brolucizumab-related retinal vasculitis: emerging disconnect between clinical trials and real world. Eye, 2021, 35, 1292-1294.	2.1	23
58	Intravitreal Anti-Vascular Endothelial Growth Factor Agents for the Treatment of Diabetic Retinopathy: A Review of the Literature. Pharmaceutics, 2021, 13, 1137.	4.5	23
59	UNDERDIAGNOSED OPTIC DISK PIT MACULOPATHY. Retina, 2019, 39, 2161-2166.	1.7	21
60	Defining Nonadherence and Nonpersistence to Anti–Vascular Endothelial Growth Factor Therapies in Neovascular Age-Related Macular Degeneration. JAMA Ophthalmology, 2021, 139, 769.	2.5	20
61	Biotherapeutics and immunogenicity: ophthalmic perspective. Eye, 2019, 33, 1359-1361.	2.1	19
62	Characteristics and outcomes of paediatric rhegmatogenous retinal detachment treated by segmental scierai buckling plus an encircling element. Eye, 2001, 15, 31-33.	2.1	18
63	CURRENT CONCEPTS AND MODALITIES FOR MONITORING THE FELLOW EYE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina, 2020, 40, 599-611.	1.7	18
64	Results in comparison between 30 gauge ultrathin wall and 27 gauge needle in sutureless intraocular lens flanged technique in diabetic patients: 24-month follow-up study. Acta Diabetologica, 2020, 57, 1151-1157.	2.5	17
65	Peripapillary hyperreflective ovoid mass-like structures—a novel entity as frequent cause of pseudopapilloedema in children. Eye, 2021, 35, 1228-1234.	2.1	17
66	Longer-acting treatments for neovascular age-related macular degeneration—present and future. Eye, 2021, 35, 1111-1116.	2.1	17
67	Real-World Performance of a Self-Operated Home Monitoring System for Early Detection of Neovascular Age-Related Macular Degeneration. Journal of Clinical Medicine, 2021, 10, 1355.	2.4	17
68	Evaluation of a Self-Imaging SD-OCT System for Remote Monitoring of Patients with Neovascular Age Related Macular Degeneration. Klinische Monatsblatter Fur Augenheilkunde, 2020, 237, 1410-1418.	0.5	17
69	Fluocinolone acetonide implant in diabetic macular edema: International experts' panel consensus guidelines and treatment algorithm. European Journal of Ophthalmology, 2022, 32, 1890-1899.	1.3	17
70	Effect of Pupil Size on Biometry Measurements Using the IOLMaster. American Journal of Ophthalmology, 2015, 159, 940-944.	3.3	16
71	<p>Wide-angled endoillumination vs traditional scleral buckling surgery for retinal detachment – a comparative study</p> . Clinical Ophthalmology, 2019, Volume 13, 287-293.	1.8	16
72	lmmunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data. Eye, 2020, 34, 1008-1009.	2.1	16

#	Article	IF	CITATIONS
73	FLUID-BASED VISUAL PROGNOSTICATION IN TYPE 3 MACULAR NEOVASCULARIZATION-FLIP-3 STUDY. Retina, 2022, 42, 107-113.	1.7	16
74	Recommendations for OCT Angiography Reporting in Retinal Vascular Disease. Ophthalmology Retina, 2022, 6, 753-761.	2.4	16
75	Herbimycin A in the treatment of experimental proliferative vitreoretinopathy: toxicity and efficacy study. Graefe's Archive for Clinical and Experimental Ophthalmology, 2000, 238, 440-447.	1.9	15
76	Intraocular pressure (IOP) after intravitreal dexamethasone implant (Ozurdex) amongst different geographic populations—GEODEX-IOP study. Eye, 2020, 34, 1063-1068.	2.1	14
77	Anti-VEGF intravitreal injections in the era of COVID-19: responding to different levels of epidemic pressure. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 567-574.	1.9	14
78	Cilioretinal artery occlusion during coronary catheterization. Acta Ophthalmologica, 1999, 77, 717-718.	0.3	13
79	Intentional retention of Descemet's membrane during keratoplasty. Acta Ophthalmologica, 2009, 69, 111-112.	1.1	13
80	Need of education on biosimilars amongst ophthalmologists: combating the nocebo effect. Eye, 2020, 34, 1006-1007.	2.1	13
81	Purification and characterization of human dehydrodolychil diphosphate synthase (DHDDS) overexpressed in E.Âcoli. Protein Expression and Purification, 2017, 132, 138-142.	1.3	12
82	Causative Pathogens of Endophthalmitis after Intravitreal Anti-VEGF Injection: An International Multicenter Study. Ophthalmologica, 2019, 241, 211-219.	1.9	12
83	Overcoming barriers of retinal care delivery during a pandemic—attitudes and drivers for the implementation of digital health: a global expert survey. British Journal of Ophthalmology, 2021, 105, 1738-1743.	3.9	12
84	Vitrectomized vs non-vitrectomized eyes in DEX implant treatment for DMO—Is there any difference? the VITDEX study. Eye, 2023, 37, 280-284.	2.1	12
85	Intentional retention of Descemet's membrane in keratoplasty for the surgical treatment of bullous keratopathy. Acta Ophthalmologica, 1993, 71, 280-282.	1.1	11
86	Massive subretinal and subretinal pigment epithelial hemorrhage displacement with perfluorocarbon liquid using a two-step vitrectomy technique. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 1341-1347.	1.9	11
87	Pharmacotherapeutic management of macular edema in diabetic subjects undergoing cataract surgery. Expert Opinion on Pharmacotherapy, 2018, 19, 1551-1563.	1.8	11
88	Ophthalmic biosimilars and biologics—role of endotoxins. Eye, 2020, 34, 614-615.	2.1	11
89	The role of steroids in treating diabetic macular oedema in the era of anti-VEGF. Eye, 2020, 34, 1003-1005.	2.1	11
90	Baseline predictors for visual acuity loss during observation in diabetic macular oedema with good baseline visual acuity. Acta Ophthalmologica, 2020, 98, e801-e806.	1.1	11

#	Article	IF	CITATIONS
91	Ranibizumab Biosimilar (Razumab) vs Innovator Ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study). Eye, 2022, 36, 1106-1107.	2.1	11
92	Reduced Activity of Geranylgeranyl Diphosphate Synthase Mutant Is Involved in Bisphosphonate-Induced Atypical Fractures. Molecular Pharmacology, 2018, 94, 1391-1400.	2.3	10
93	Biologics, biosilimars, and biobetters: different terms or different drugs?. Eye, 2019, 33, 1032-1034.	2.1	10
94	Structural Characterization of Full-Length Human Dehydrodolichyl Diphosphate Synthase Using an Integrative Computational and Experimental Approach. Biomolecules, 2019, 9, 660.	4.0	10
95	The outcome of fluocinolone acetonide intravitreal implant is predicted by the response to dexamethasone implant in diabetic macular oedema. Eye, 2021, 35, 3232-3242.	2.1	10
96	Photodynamic therapy as a treatment option for peripapillary pachychoroid syndrome: a pilot study. Eye, 2022, 36, 716-723.	2.1	10
97	Spontaneous thrombosis of a traumatic cavernous sinus fistula. Brain Injury, 1993, 7, 547-550.	1.2	9
98	MII RetCam assisted smartphone-based fundus imaging (MSFI)—A boon for paediatric retinal imaging. Eye, 2020, 34, 1307-1309.	2.1	9
99	Understanding the Mechanisms of Fluid Development in Age-Related Macular Degeneration. Ophthalmology Retina, 2021, 5, 105-107.	2.4	9
100	Macular Hole Surgery with Internal Limiting Membrane Peeling Facilitated by Membrane-Blue® versus Membrane-Blue-Dual®: A Retrospective Comparative Study. Journal of Ophthalmology, 2016, 2016, 1-6.	1.3	8
101	Retinal Toxicity of Intravitreal Injection of Ziv-Aflibercept in Albino Rabbits. Translational Vision Science and Technology, 2018, 7, 23.	2.2	8
102	Noninfectious Inflammatory Response following Intravitreal Bevacizumab Injections: Description of a Cluster of Cases in Two Centers and a Review of the Literature. Ophthalmologica, 2018, 240, 163-166.	1.9	8
103	Long-term visual outcome and its predictors in macular oedema secondary to retinal vein occlusion treated with dexamethasone implant. British Journal of Ophthalmology, 2019, 103, 463-468.	3.9	8
104	A NOVEL FINDING OF HYPERREFLECTIVE MATERIAL IN THE SILICONE-RETINA INTERFACE. Retina, 2020, 40, 2055-2060.	1.7	8
105	SUSPENDING TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN CASES OF FUTILITY. Retina, 2020, 40, 1010-1020.	1.7	8
106	Communicating with patients with nAMD and their families during the COVID-19 pandemic. Graefe's Archive for Clinical and Experimental Ophthalmology, 2020, 258, 1335-1337.	1.9	8
107	Novel Long-acting Pharmacotherapy for Exudative Age Related Macular Degeneration. Current Pharmaceutical Design, 2019, 24, 4860-4863.	1.9	8
108	Variable Phenotypic Expressivity of Best's Vitelliform Dystrophy. Ophthalmic Paediatrics and Genetics, 1993, 14, 131-136.	0.4	7

#	Article	IF	CITATIONS
109	Overexpression and Purification of Human <em>Cis</em> -prenyltransferase in <em>Escherichia coli</em> . Journal of Visualized Experiments, 2017, , .	0.3	7
110	Carotid Artery Endarterectomy Effect on Choroidal Thickness: One-Year Follow-Up. Journal of Ophthalmology, 2018, 2018, 1-8.	1.3	7
111	Brolucizumab: is extended VEGF suppression on the horizon?. Eye, 2020, 34, 424-426.	2.1	7
112	Smartphone based ROP (S-ROP) screening—opportunities and challenges. Eye, 2020, 34, 1512-1514.	2.1	7
113	Pachydrusen: the epidemiology of pachydrusen and its relevance to progression of pachychoroid disease spectrum. Eye, 2020, 34, 1501-1503.	2.1	7
114	Brolucizumab—another anti-VEGF or beyond. Eye, 2020, 34, 1499-1500.	2.1	7
115	Terms non-exudative and non-neovascular: awaiting entry at the doors of AMD reclassification. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 1381-1383.	1.9	7
116	Dapiprazole for patients with night haloes after excimer keratectomy. Graefe's Archive for Clinical and Experimental Ophthalmology, 1996, 234, S139-S141.	1.9	6
117	Macular ring in a patient with Terson's syndrome. Acta Ophthalmologica, 1999, 77, 599-600.	0.3	6
118	Safety of intravitreal clindamycin in albino rabbit eyes. Documenta Ophthalmologica, 2017, 135, 133-146.	2.2	6
119	Subretinal Fluid Optical Density and Spectral-Domain Optical Coherence Tomography Characteristics for the Diagnosis of Circumscribed Choroidal Hemangioma. Ophthalmologica, 2019, 241, 195-201.	1.9	6
120	Outcomes following Laser Retinopexy for Retinal Tears: A Comparative Study between Trainees and Specialists. Ophthalmologica, 2020, 243, 355-359.	1.9	6
121	Notion of tolerating subretinal fluid in neovascular AMD: understanding the fine print before the injection pause. British Journal of Ophthalmology, 2021, 105, 149-150.	3.9	6
122	Avoiding Diagnostic Lens Fogging During the COVID-19 Era. Clinical Ophthalmology, 2020, Volume 14, 4507-4509.	1.8	6
123	Fluid-based prognostication in n-AMD: Type 3 macular neovascularisation needs an analysis in isolation. British Journal of Ophthalmology, 2021, 105, 297-298.	3.9	6
124	Macular Hemorrhage Due to Age-Related Macular Degeneration or Retinal Arterial Macroaneurysm: Predictive Factors of Surgical Outcome. Journal of Clinical Medicine, 2021, 10, 5787.	2.4	6
125	Use of Home Device for Early Detection of Neovascular Age-Related Macular Degeneration. Ophthalmic Research, 2012, 48, 11-15.	1.9	5
126	Metal Coordination Is Crucial for Geranylgeranyl Diphosphate Synthase–Bisphosphonate Interactions: A Crystallographic and Computational Analysis. Molecular Pharmacology, 2019, 96, 580-588.	2.3	5

#	Article	IF	CITATIONS
127	Brolucizumab: the road ahead. British Journal of Ophthalmology, 2020, 104, 1631-1632.	3.9	5
128	Current role of intravitreal injections in Irvine Gass syndrome-CRIIG study. International Ophthalmology, 2020, 40, 3067-3075.	1.4	5
129	Clinical characteristics and visual outcomes of non-resolving subretinal fluid in neovascular AMD despite continuous monthly anti-VEGF injections: a long-term follow-up. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 1153-1160.	1.9	5
130	Vortex vein anastomosis and pachychoroid—an evolving understanding. Eye, 2021, 35, 1545-1547.	2.1	5
131	On label bevacizumab for retina: where it stands. Eye, 2022, 36, 916-917.	2.1	5
132	The management of neovascular ageâ€related macular degeneration: A systematic literature review of patientâ€reported outcomes, patient mental health and caregiver burden. Acta Ophthalmologica, 2023, 101, .	1.1	5
133	The relation of somatotypes and stress response to central serous chorioretinopathy. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 2307-2315.	1.9	4
134	Prevalence of choroidal nevus and retinal pigment epithelial alterations in vitiligo patients. Graefe's Archive for Clinical and Experimental Ophthalmology, 2018, 256, 927-933.	1.9	4
135	Understanding Intravitreal Silicone Oil Droplets Due to Intravitreal Injections. Retina, 2019, Publish Ahead of Print, 1233-1235.	1.7	4
136	MULTIPLE INTRAVITREAL INJECTIONS DO NOT CAUSE ANTERIOR SCLERAL THINNING. Retina, 2021, 41, 768-773.	1.7	4
137	Faricimab: Two in the Bush Is Proving Better than One in the Hand?. Ocular Immunology and Inflammation, 2022, 30, 1961-1963.	1.8	4
138	Should we still be performing macular laser for non-centre involving diabetic macular oedema? Yes. Eye, 2022, 36, 483-484.	2.1	4
139	Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies. Eye, 2023, 37, 1242-1248.	2.1	4
140	Spontaneous resolution of proliferative vitreoretinopathy. Acta Ophthalmologica, 1992, 70, 549-550.	1.1	3
141	Optical coherence tomography angiography findings in diabetic retinopathy. Expert Review of Ophthalmology, 2017, 12, 475-484.	0.6	3
142	MULTIMODAL IMAGING OF CHOROIDAL AND OPTIC DISK VESSELS NEAR OPTIC DISK PITS. Retinal Cases and Brief Reports, 2020, 14, 289-296.	0.6	3
143	EVALUATION OF ACCURACY AND UNIFORMITY OF THE NOMENCLATURE OF VITREORETINAL INTERFACE DISORDERS. Retina, 2020, 40, 1272-1278.	1.7	3
144	Brolucizumab-key learnings from HAWK and HARRIER. Eye, 2020, 34, 1318-1320.	2.1	3

#	Article	IF	CITATIONS
145	Expert opinion on the management and follow-up of uveitis patients during SARS-CoV-2 outbreak. Expert Review of Clinical Immunology, 2020, 16, 651-657.	3.0	3
146	Communicating with patients requiring anti-VEGF intravitreal injections and their families during the COVID-19 pandemic: an update. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 795-797.	1.9	3
147	GRAding of functional and anatomical response to DExamethasone implant in patients with Diabetic Macular Edema: GRADE-DME Study. Scientific Reports, 2021, 11, 4738.	3.3	3
148	Retinal Lineage Therapeutic Specific Effect of Human Orbital and Abdominal Adipose-Derived Mesenchymal Stem Cells. Stem Cells International, 2021, 2021, 1-15.	2.5	3
149	Current and Future Treatments for Diabetic Retinopathy. Pharmaceutics, 2022, 14, 812.	4.5	3
150	Prevention of the rise in intraocular pressure following neodymium‥AG posterior capsulotomy using topical clonidine. Acta Ophthalmologica, 1991, 69, 462-465.	1.1	2
151	Long-term outcomes of triamcinolone acetonide–assisted anterior vitrectomy during complicated cataract surgery with vitreous loss. Journal of Cataract and Refractive Surgery, 2014, 40, 722-727.	1.5	2
152	Infliximab exerts a dose-dependent effect on retinal safety in the albino rabbit. Documenta Ophthalmologica, 2017, 135, 175-185.	2.2	2
153	The Management of Retinal Detachment: Techniques and Perspectives. Journal of Ophthalmology, 2017, 2017, 1-2.	1.3	2
154	The Management of Retinal Detachment: Techniques and Perspectives 2018. Journal of Ophthalmology, 2019, 2019, 1-2.	1.3	2
155	Initial treatment of macular oedema due to central retinal vein occlusion—which anti-VEGF agent to choose?. Eye, 2020, 34, 219-220.	2.1	2
156	Spontaneous Hyphema from Iris Microhemangiomatosis in an Elderly Patient with Hypertensive Crisis. Case Reports in Ophthalmology, 2020, 11, 68-72.	0.7	2
157	PIGMENT EPITHELIAL DETACHMENT IN AGE-RELATED MACULAR DEGENERATION. Retina, 2021, 41, 2229-2235.	1.7	2
158	Development in Smartphone Technologies and the Advancement of Home Vision Monitoring. JAMA Ophthalmology, 2022, 140, 161.	2.5	2
159	Bevacizumab versus ranibizumab for the treatment of neovascular age-related macular degeneration. Expert Review of Ophthalmology, 2010, 5, 603-615.	0.6	1
160	Surgical treatment for diabetic macular edema. Expert Review of Ophthalmology, 2016, 11, 173-179.	0.6	1
161	Subfoveal Neurosensory Detachment Flattening and Observe (SNF-Ob): A Novel Approach in Diabetic Macular Edema Management. Ophthalmology Retina, 2019, 3, 1009-1011.	2.4	1
162	How to manage patients with center-involving diabetic macular edema and good visual acuity? An answer to a common clinical question. Eye, 2019, 33, 1677-1678.	2.1	1

#	Article	IF	CITATIONS
163	Autologous Corneal Transplant from an Enucleated Fellow Eye for Choroidal Melanoma: A Case Report. Case Reports in Ophthalmology, 2020, 11, 181-188.	0.7	1
164	Avoiding Diagnostic Lens Fogging During the COVID-19 Era: Options to Consider [Response To Letter]. Clinical Ophthalmology, 2021, Volume 15, 387-388.	1.8	1
165	Is there a light at the end of the gender inequality tunnel?. Clinical and Experimental Ophthalmology, 2021, 49, 649-651.	2.6	1
166	Evaluation of a Telemedicine Model for Following Keratoconus Patients in the Era of COVID-19 Pandemic. Telemedicine Journal and E-Health, 2022, 28, 1023-1027.	2.8	1
167	Reply. Retina, 2022, 42, e20-e22.	1.7	1
168	Transient phacodonesis after circling buckle procedure for rhegmatogenous retinal detachment. Eye, 2001, 15, 350-351.	2.1	0
169	Unintentional intraocular injection of corticosteroids. Acta Ophthalmologica, 2009, 71, 717-718.	1.1	0
170	Opening by the Nd:YAG laser of the anterior portion of the capsular bag in the treatment of delayed onset pseudophakic endophthalmitis. Acta Ophthalmologica, 1994, 72, 267-268.	1.1	0
171	Intravitreal Trimethoprim and Sulfamethoxazole Toxicity to the Retina of Albino Rabbits. Translational Vision Science and Technology, 2018, 7, 2.	2.2	0
172	Reply. Ophthalmology, 2018, 125, e61-e62.	5.2	0
173	A Patient With Type 1 Diabetes, Visual Acuity Loss, and Retinal Thickening. JAMA Ophthalmology, 2019, 137, 1078.	2.5	0
174	Low-Intensity Laser Light Projection for Improved Reading Abilities in Low-Vision Patients. Current Eye Research, 2021, 46, 271-276.	1.5	0
175	Evaluation of Accuracy and Agreement of Optical Coherence Tomography Angiography Interpretation of Common Retinal Findings and Diagnoses. Ophthalmologica, 2021, 244, 141-149.	1.9	0
176	Activation of a Quiescent Choroidal Neovascularization in a Patient with Age-Related Macular Degeneration. Case Reports in Ophthalmology, 2021, 12, 433-437.	0.7	0
177	Perspectives on remote patient monitoring with self-operated OCT for management of neovascular age-related macular degeneration. Expert Review of Ophthalmology, 0, , 1-5.	0.6	0
178	Response to: Comment on: "Peripapillary hyperreflective ovoid mass-like structures—a novel entity as frequent cause of pseudopapilloedema in children― Eye, 2022, , .	2.1	0
179	IMPACT OF COVID-19 PANDEMIC LOCKDOWNS ON VISUAL ACUITY OF PATIENTS WITH NEOVASCULAR AMD. Retina, 2022, 42, 1529-1535.	1.7	0
180	Brolucizumab in polypoidal choroidal vasculopathy. Expert Opinion on Biological Therapy, 2022, 22, 809-812.	3.1	0